Global Humanized Mouse and Rat Model Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2032

Global Humanized Mouse and Rat Model Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2032

Global Humanized Mouse and Rat Model Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 – 2032

Global Humanized Mouse and Rat Model market was valued US $255 Million in 2022 and is expected to reach ~US $465 Million by 2032, growing at a CAGR of 6.2% during the forecast period 2023-2032.

For use in scientific and medical research, humanised mouse and rat models are specialised instruments that include functioning human genes, cells, tissues, and organs. These models are used to simulate both healthy and pathological states of the human immune system. These humanised mouse and rat models are used for a number of purposes, such as basic science, evaluating the safety of large molecule medicines, simulating specific infectious diseases unique to humans, and assessing the efficacy of immunotherapy techniques. They accomplish this by inhibiting the relevant mouse proteins in both cells and tissues, while simultaneously expressing human proteins. Preclinical testing can be greatly aided by the use of humanised mouse and rat models, which allow for the replication of pathological circumstances found in humans, the evaluation of the effectiveness of compounds, and the measurement of their effects on human proteins.

A growing number of research projects using humanised models, an increasing need for personalised medicine, an increase in R&D activity within pharmaceutical and biotechnology companies, and consistent support from grants and investments from the public and private sectors are the main factors propelling the growth of the humanised mouse and rat model market.

The need for humanised mouse and rat models is predicted to rise as scientists look for more precise disease models that closely resemble human physiology for non-clinical research and medication discovery. In particular, the increasing validation of the efficacy of humanised mouse models in research investigations has led to a growing need for them in immuno-oncology research.

In order to obtain a more profound comprehension of human innate immunity and adaptive immunity, the creation of advanced humanised mouse models is now in progress. Oncology research is expected to make great progress thanks to these developments. As a result, in order to accommodate different research applications, market participants are actively diversifying their portfolios. The hu-CD34 (Humanised CD34+) mouse platform, for example, is provided by THE JACKSON LABORATORY in the United States and is intended for use in vivo investigation of the safety and effectiveness of new immune-modulating medicines. In a similar vein, genOway in France offers validated humanised models for allergy and inflammatory research in mice, which are ideal for evaluating the safety and in vivo effectiveness of biologics and treatment candidates.

In the field of precision medicine, also known as personalised medicine, unique biomarkers are used to customise therapies. Researchers have turned to mice in their quest to create patient-specific cancer models (PDX models). These models are created by injecting immune-compromised animals with tumour components. Then, every mouse adheres to a different course of treatment, so forming discrete strategies for patient tumour reduction. It is anticipated that the usage of humanised mouse models would increase demand for customised pharmaceuticals. For example, the Jackson Laboratory has created more than 450 distinct PDX oncology mice models for a variety of illnesses, including as acute myeloid leukaemia (AML) and cancers of the bladder, breast, lung, pancreas, and ovaries. The development of related instruments, technology, and scientific research has expedited the field of customised medicine. In the upcoming years, it is anticipated that these reasons would drive the market for humanised mouse models to grow.

“Genetic humanized mouse models segment, by type, to be dominating market from 2023 to 2030.”

On the basis of type, the market is segmented into genetic humanized mouse models and cell-based humanized mouse models. The market is going to see a dominant force emerge in the genetically humanised mouse models category. The primary cause of this prominence is the extensive use of genetically modified mice as models in a range of experimental investigations, especially those evaluating the efficacy and safety of drugs. The market for humanised mouse models is growing in terms of revenue due to the growing usage of these models to investigate medication metabolism and disposition. The genetically modified mouse model section is important because it plays a key role in accelerating drug development. Genetically modified mice models remain a vital tool for drug discovery and experimental analysis, utilised by research organisations, pharmaceutical corporations, and biotech companies. This strengthens their standing as the industry's main source of revenue.

“Oncology segment, by application, to be dominating market from 2023 to 2030.”

Regarding the application breakdown, the Humanized Mouse and Rat Model market is categorized into Oncology, Immunology, Neuroscience, Toxicology, Infectious Diseases and other applications. The market for humanised mouse models is growing at the fastest rate due to the oncology sector. Humanised mouse models are essential to oncology research, which is a major field that understands cancer biology, develops new treatments, and assesses the effectiveness of medications. These models closely mimic the microenvironment of a human cancer, enabling more accurate and trustworthy preclinical research.

In light of the pressing need for innovative research on cancer and the creation of novel treatments, the oncology market continues to dominate. In this discipline, there will likely be a strong need for humanised mouse models as long as cancer is a major worldwide health concern. This ongoing need is probably going to drive advancement and creativity in cancer treatments.

“North America to be largest region in Humanized Mouse and Rat ModelMarket.”

The encephalitis treatment market is segmented into four regions: North America, Europe, Asia-Pacific, and Others. Others are split up into South America and the Middle East.

North America's market for humanised mouse models is expected to increase significantly. Preclinical research involving humanised mouse models is required for drug development, a trend spurred by the growing need for personalised medicine. Humanised mouse models that are more accurate and applicable have been made possible by developments in genome editing and genetic engineering. In North America, academic institutions and pharmaceutical corporations are depending more and more on these models to research human diseases and assess possible therapies. The region's strong healthcare infrastructure and large financial outlays for biomedical research are factors that bode well for the mouse model market in North America going forward.

Similar to this, the European market for rat and mouse models is expected to grow because of its significant contribution to the advancement of drug development and scientific research. This region's strong dedication to cutting-edge research and innovative healthcare practices is driving the adoption of humanised mouse models. The precision and applicability of these models have been greatly enhanced by advancements in gene editing technologies. Humanised mouse models are being used more often by academic institutions and pharmaceutical companies in Europe to research diseases, evaluate possible therapies, and create personalised medicine strategies. With significant investments in the life sciences sector and a strong healthcare infrastructure, the European market is well-positioned to become a centre for the creation of humanised mouse models.

In the upcoming years, the humanised mouse model market in Asia Pacific is anticipated to grow at a rapid pace. The flourishing biotechnology and pharmaceutical industries, as well as the expanding emphasis on precision medicine, are the main drivers of this rise and the rising usage of humanised mouse models in preclinical research. More complex and pertinent models have been produced as a result of developments in genome editing and genetic engineering, increasing their usefulness for drug testing and illness modelling. In Asia Pacific, pharmaceutical corporations, academic institutions, and research organisations are progressively incorporating these models into their research workflows. Thanks to rising healthcare infrastructure and increased investments, the Asia Pacific region is becoming a major player in the global market for humanised mouse models. There is tremendous opportunity for innovation and scientific improvement in this industry.

Humanized Mouse and Rat ModelCompetitive Landscape

The competitive landscape of the Humanized Mouse and Rat ModelMarket involves assessing the competitive landscape to understand the strengths, weaknesses, opportunities, and threats of the industry. Key industry players have recognized that the adoption of Humanized Mouse and Rat Modeltechnology holds the potential for further growth. The growing desire among producers to optimize their production costs has spurred collaborative efforts among companies to scale up their production capacity. This strategic collaboration not only aims to increase revenue but also seeks to establish dominance in the market.

The Humanized Mouse and Rat ModelMarket is highly competitive, with numerous companies vying for market share. Prominent companies in the Humanized Mouse and Rat ModelMarket include:

Major Players:

Harbour Antibodies BV

Champions Oncology Inc.

Hera Biolabs

Charles River Laboratories

Crown Bioscience Inc.

Ingenious Targeting Laboratory

Genoway S.A.

Inotiv, Horizon Discovery Group Plc

Oncodesign

Humurine Technologies

Recent Developments:

Taconic Biosciences, a prominent supplier of animal models for pharmaceutical research, unveiled the huNOG-EXL EA humanised immune system (HIS) mouse in January 2022. With this addition, Taconic's already impressive HIS portfolio is increased, and the research potential of myeloid-lineage HIS mice models is much enhanced.

The Research Models & Services (RMS) section of Charles River Laboratories Japan was acquired by nonprofit biomedical research organisation The Jackson Laboratory (JAX) in October 2021, making it a wholly-owned subsidiary. With headquarters in Japan, The Jackson Laboratory Japan is a recently established company with about 250 employees spread among three production sites in Atsugi, Hino, and Tsukuba as well as an administrative office in Yokohama.